Scientia reports that while diabetes is the largest segment of the POC testing market, infectious disease testing, a smaller segment, has high growth potential due to (1) increasing awareness of public health problems such as flu, chlamydia and hospital-acquired infections (2) potential availability of disruptive, point-of-care molecular diagnostics and (3) increased adoption of POC testing in emerging markets.

Other main findings:

While the US is a major influencer in the global POC testing market, the developing world will experience the fastest growth ”especially in China and India, where the governments plan to open thousands of rural clinics. The emergence of rapid clinics has contributed to POC market growth. However, in the current economic slowdown, US retail giants such as CVS and Wal-Mart have closed many clinics. As a result, rapid clinics may need new strategies, such as partnering with hospitals, to remain viable. Next-generation, portable, easy-to-use technologies, which promise greater accuracy, convenience and clinical impact, will fuel the growth of many POC segments. Stringent regulatory and reimbursement requirements and a need for pharmaco-economic studies remain barriers to widespread POC adoption in the US and abroad.

Source : Scientia Advisors